Reported about 4 hours ago
Biogen anticipates a drop in profits for 2025 due to a stronger dollar and increased competition for its multiple sclerosis drugs, despite outperforming fourth quarter expectations thanks to cost-cutting measures and the launch of new products, including an Alzheimer's drug.
Source: YAHOO